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Abstract
The indication for performing an allogeneic hematopoietic stem cell transplantation (allo-HCT) in patients with isolated
trisomy 8 AML in first complete remission (CR) is still debated. Here, we compared outcomes of such patients given either
allo-HCT or autologous (auto)-HCT. Inclusion criteria consisted of adult patients with de novo AML, isolated trisomy 8, first
HCT between 2000 and 2018, CR1 at transplantation, and either auto-HCT or allo-HCT with a HLA-identical sibling donor
(MSD) or a 10/10 HLA-matched unrelated donor (UD 10/10). A total of 401 patients met the inclusion criteria. They
underwent an auto-HCT (n= 81), allo-HCT with a MSD (n= 186) or allo-HCT with a 10/10 UD (n= 134). At 3 years,
relapse incidence, nonrelapse mortality and leukemia-free survival (LFS) were 59%, 5%, and 37%, respectively, in auto-
HCT recipients; 31% (P < 0.001), 14% (P= 0.04), and 55% (P= 0.033), respectively, in MSD recipients and 29% (P <
0.001), 13% (P= 0.15), and 59% (P= 0.03), respectively, in UD 10/10 recipients. In multivariate analysis, in comparison to
auto-HCT, MSD and UD 10/10 were associated with a lower risk of relapse (HR= 0.47, P < 0.001 and HR= 0.40, P <
0.001, respectively) translating to better LFS (HR= 0.69, P= 0.04 and HR= 0.60, P= 0.03, respectively). There was also a
similar trend for overall survival (HR= 0.73, P= 0.12 and HR= 0.65, P= 0.08).
Introduction
Trisomy 8 is one of the most frequent cytogenetic
abnormality in acute myeloid leukemia (AML), occurring in
10–15% of AML patients and being the sole genetic
abnormality in ~5% of AML [1, 2]. Although allogeneic
hematopoietic stem cell transplantation (allo-HCT) has been
frequently used in first complete remission (CR) in younger,
fit AML patients with isolated trisomy 8 [3, 4], there has
been a paucity of data comparing allo-HCT to autologous
hematopoietic stem cell transplantation (auto-HCT)
or consolidation chemotherapy in these patients [2].
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Specifically, the only large study reported to date assessing
the impact of allo-HCT (versus other approaches) included
data from 131 patients with trisomy 8 or trisomy 8 plus one
additional aberration, and who were treated between 1993
and 2002 in 1 of 8 German AMLSG trials [5]. Among them,
72 patients were eligible for post-remission therapy and
received either high-dose cytarabine (n= 43), auto-HCT
(n= 10), or allo-HCT (n= 19, including 14 with a HLA-
matched sibling donor (MSD) and 5 with an unrelated
donor (UD)). In multivariate analysis, allo-HCT was asso-
ciated with better leukemia-free survival (LFS) but was not
a prognostic factor for overall survival (OS).
It is now well established that the curative power of allo-
HCT relies largely on immune-meditated graft-versus-
leukemia effects [6–8]. Prior studies have observed that
CD34+ cells from patients with myelodysplastic syndrome
harboring trisomy 8 are more sensitive to Fas-mediated
apoptosis [9]. One could argue that this might increase their
susceptibility to graft-versus-leukemia effects [10]. In con-
trast, AML blasts from isolated trisomy 8 patients were
shown to exhibit lower expression of several proapoptotic
genes than AML blasts from AML patients with a normal
karyotype [11], perhaps limiting their susceptibility to be
killed by donor immune cells.
Based on these considerations, in the current study we
elected to compare transplantation outcomes of AML
patients with isolated trisomy 8 in first CR who underwent
auto-HCT versus allo-HCT from either a MSD or a 10/10
HLA-matched unrelated (UD 10/10) donor.
Patients and methods
Inclusion criteria
This is a retrospective study from the acute leukemia
working party (ALWP) of the European Society for Blood
and Marrow Transplantation (EBMT). The EBMT registry
is a voluntary working society of more than 600 transplant
centers, participants of which are required once a year to
report all consecutive HCT and follow-up. Audits are rou-
tinely performed to check for data accuracy.
Inclusion criteria included adult patients (defined as ≥18
years of age at transplantation), de novo AML, isolated
trisomy 8, first HCT between 2000 and 2018, CR1 at
transplantation, and either auto-HCT or allo-HCT with
either a MSD or an UD 10/10.
Definitions
Reduced intensity conditioning (RIC) was defined as regi-
mens combining fludarabine with either <6 Gy total body
irradiation (TBI), ≤8 mg/kg busulfan, or ≤140 mg/m2
melphalan, or with other nonmyeloablative drugs as pre-
viously reported [12, 13]. Acute and chronic graft-versus-
host disease (GVHD) was graded according to previously
reported criteria [14].
Statistical analyses
Analyses were carried out on data from all patients meeting
the inclusion/exclusion criteria. Start time was the day of
either auto-HCT or allo-HCT for all endpoints. Patients
were censored at the time of last follow-up. Relapse was
defined as the presence of 5% bone marrow blasts and/or
reappearance of the underlying disease. Nonrelapse mor-
tality was defined as death without evidence of relapse or
progression. OS was defined as the time from allo-HCT to
death, regardless of the cause. Events in the composite
endpoint LFS included relapse and death, whichever
occurred first. The Kaplan–Meier method was used to
estimate the probabilities of OS and LFS.
Cumulative incidence functions were used to estimate
relapse incidence and nonrelapse mortality in a competing
risk setting. Relapse and death were treated as competing
events for analyses assessing cumulative incidences of acute
or chronic GVHD.
Univariate analyses were performed using Gray’s test for
cumulative incidence functions and the log-rank test for OS
and LFS.
Multivariate Cox models were used to adjust the com-
parison of transplantation outcomes between patients given
an auto-HCT versus either an allo-HCT with MSD or an an
allo-HCT with a UD 10/10 donor. Factors included in the
model consisted of time from diagnosis to transplantation,
patient age, and year of transplantation. Further, in order to
take into account the heterogeneity in the effect of a char-
acteristic or a treatment across centers, we introduced a
random effect (also named frailty effect) in Cox multivariate
models [15]. Then, the same random effect was shared by
all patients within the same center. All tests were two sided.
The type I error rate was fixed at 0.05 for determination of
factors associated with time to event outcomes. Statistical
analyses were performed with SPSS 19 (SPSS Inc, Chicago,




Data from 401 patients meeting the inclusion/exclusion
criteria of the study were included in the current analysis.
Eighty-one received an auto-HCT, and 320 an allo-HCT
from either a MSD (n= 186) or an UD 10/10 (n= 134).
462 F. Baron et al.
Age at transplantation and Karnofsky performance status
were comparable in the three groups (Table 1). In contrast,
median year of transplantation was earlier in auto-HCT
patients (2006) than in MSD (2011) or UD 10/10 (2015)
patients (global P < 0.001). The stem cell source was per-
ipheral blood stem cells in 94% of auto-HCT patients, 76%
of MSD patients, and 85% of UD 10/10 recipients (global
P= 0.002). The proportion of patients with mutated NPM1
or FLT3-ITD was comparable within the 3 groups. Finally,
among allo-HSCT recipients, the proportion of patients
given grafts after RIC regimen was 48% in MSD and 58%
in UD 10/10 patients, respectively.
Engraftment and GVHD
Graft failure occurred in one auto-HCT (1%), four
MSD (2%), and two UD 10/10 (1%) patients, respectively.
Median time to achieve 500 neutrophils was 14 days (IQR
12–17 days) in auto-HCT patients, 16 days (IQR 14–20 days)
among MSD patients, and 18 (IQR 15–21 days) among UD
10/10 recipients (global P < 0.001).
Among MSD patients, grade II, III and IV acute GVHD
was observed in 27 (15%), 7 (4%), and 5 (3%) patients,
respectively. In UD 10/10 recipients the figures were 29
(22%), 11 (8%), and 5 (4%), respectively. The 2-year
cumulative incidence of chronic GVHD was 42% in MSD
recipients and 43% in UD 10/10 patients.
Relapse and nonrelapse mortality
The 3-year cumulative incidence of relapse was 59% (95%
confidence interval (CI): 46–69%) in auto-HCT patients,
31% (95% CI: 24–38%) in MSD recipients (P= 0.0002 in
comparison to auto-HCT), and 29% (95% CI: 20–38%) in
UD 10/10 recipients (P < 0.0001 in comparison to auto-HCT)
(Fig. 1). These observations held true in FLT3 wild-type
patients, in those with wild-type NPM1 and in those with
both FLT3 and NPM1 wild-type (Supplementary Table 1).
In addition, these observations held also true in patients
transplanted from 2000 to 2009 as well as in those trans-
planted from 2010 to 2018 (Supplementary Table 2). Further,
combining data from MSD and UD 10/10 patients, there was
no impact of conditioning intensity on the relapse risk (P=
0.75). In multivariate analysis, in comparison to auto-HCT,
allo-HCT with MSD (Hazard ratio (HR)= 0.47, 95% CI:
0.31–0.72; P= 0.0006) or UD 10/10 (HR= 0.40, 95% CI:
0.24–0.67; P= 0.0005) were each associated with a lower
risk of relapse (Table 2) while there was no interaction
between donor type and year of transplantation and the risk
of relapse.
The 3-year cumulative incidence of nonrelapse mortality
was 5% (95% CI: 1–12%) in auto-HCT patients, 14% (95%
CI: 9–20%) in MSD recipients (P= 0.04 in comparison to
auto-HCT), and 13% (95% CI: 8–20%) in UD 10/10 reci-
pients (P= 0.15 in comparison to auto-HCT) (Fig. 1).
These observations held true in patients transplanted from
2000 to 2009 as well as in those transplanted from 2010 to
2018 (Supplementary Table 2). Further, combining data
from MSD and UD 10/10 patients, there was no impact of
conditioning intensity on nonrelapse mortality (P= 0.52).
In multivariate analysis, in comparison to auto-HCT, allo-
HCT with MSD was associated with a higher nonrelapse
mortality (HR= 2.67, 95% CI: 1.0–6.9; P= 0.04). Allo-
HCT with UD 10/10 showed a trend toward a higher non-
relapse mortality (HR= 2.55, 95% CI: 0.86–7.5; P= 0.09)
compared with auto-HCT (Table 2). There was no interac-
tion between donor type and year of transplantation and the
risk of nonrelapse mortality.
LFS and OS
The 3-year LFS was 37% (95% CI: 25–48%) in auto-HCT
patients, 55% (95% CI: 47–63%) in MSD recipients (P=
0.03 in comparison to auto-HCT), and 59% (95% CI:
49–68%) in UD 10/10 recipients (P= 0.003 in comparison
to auto-HCT) (Fig. 2). These observations held true in FLT3
wild-type patients, in those with wild-type NPM1 and in
those with both FLT3 and NPM1 wild-type (Supplementary
Table 1). Further, combining data from MSD and UD 10/10
patients, there was no impact of conditioning intensity on
LFS (P= 0.50). In multivariate analysis, in comparison to
auto-HCT, allo-HCT with MSD (HR= 0.69, 95% CI:
0.48–0.99; P= 0.044) or UD 10/10 (HR= 0.60, 95% CI:
0.39–0.94; P= 0.027) were each associated with better LFS
(Table 2). There was no interaction between donor type and
year of transplantation and LFS.
The 3-year OS was 50% (95% CI: 38–61%) in auto-
HCT patients, 63% (95% CI: 55–70%) in MSD recipients
(P= 0.054 in comparison to auto-HCT), and 69% (95%
CI: 60–78%) in UD 10/10 recipients (P= 0.01 in com-
parison to auto-HCT) (Fig. 2). Further, combining data
from MSD and UD 10/10 patients, there was no impact of
conditioning intensity on OS (P= 0.48). In multivariate
analysis, in comparison to auto-HCT, there was no dif-
ference between allo-HCT with MSD (HR= 0.73, 95%
CI: 0.5–1.1; P= 0.12) or with UD 10/10 (HR= 0.65,
95% CI: 0.4–1.1; P= 0.08), with respect to OS (Table 2).
There was no interaction between donor type and year of
transplantation and OS.
Among auto-HCT recipients, the main causes of death
were leukemia (56%), infections (19%), and hemorrhage
(9%). Among MSD recipients, the main causes of death
were leukemia (51%), infections (25%), and GVHD
(16%). Among UD 10/10 recipients, the main causes
of death were leukemia (38%), GVHD (27%), and
infections (22%).
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Auto vs MSD Auto vs
UD 10/10
Follow-up (reverse KM, in
months), median (IQR)
72 (47–124) 62 (20–98) 35 (13–57) 0.20 <0.001
Patient age at transplant
(year), median (Min-Max)
52 (20–72) 51 (18–74) 54 (19–76) 0.36 0.56
Patient sex, n (%) 0.56 0.11
Male 40 (49) 99 (53) 81 (60)
Female 41 (51) 87 (47) 53 (40)
Karnofsky score, n (%) 0.67 1
≤80 1 (1) 5 (3) 2 (2)
>80 75 (99) 157 (97) 124 (98)
Missing 5 24 8
Diagnosis to transplant (in
months), median (IQR)











Non-mutated 35 (76) 92 (85) 80 (85)
Mutated 11 (24) 16 (15) 14 (15)
Missing 35 78 40
FLT3-ITD, n (%) 0.9 0.16
No 37 (77) 87 (76) 67 (66)
Yes 11 (23) 27 (24) 35 (34)
Missing 33 72 32
Female to male, n (%)
No 81 (100) 145 (78) 113 (84)
Yes 0 40 (22) 21 (16)
Missing 0 1 0
Cell sources, n (%) <0.001 0.06
Bone marrow 5 (6) 44 (24) 20 (15)
PBSC 75 (94) 142 (76) 114 (85)
Missing 1 0 0
Conditioning, n (%)
BuCy 25 (36) 53 (28) 18 (13)
BuFlu 1 (1) 53 (28) 63 (47)
FluMel 0 18 (10) 6 (4)
BuMel 13 (19) 0 0
BuVP16 9 (13) 0 0
CyTBI 4 (6) 17 (9) 6 (4)
FluTBI 0 13 (7) 13 (10)
Other 18 (26) 32 (17) 28 (21)
Missing 11 0 0
Conditioning type, n (%)
Myeloablative 96 (52) 56 (42)
Reduced intensity [4] 90 (48) 78 (58)
In vivo TCD, n (%)
No 81 (100) 130 (70) 33 (25)
Yes 0 55 (30) 101 (75)
ATG 37 94
Alemtuzumab 18 7
Missing 0 1 0
HCT hematopoietic stem cell transplantation, Auto-HCT autologous HCT, Allo-HCT allogeneic HCT, MSD HLA-matched sibling donor, UD 10/
10 HLA-matched unrelated donor, IQR interquartile range, PBSC peripheral blood stem cells, Bu busulfan, Cy, cyclophosphamide, Flu
fludarabine, Mel melphalan, TBI total body irradiation.
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Second transplantation after relapse
A total of 36 patients received a further allo-HCT after
relapse. This include 17 out of 46 relapses (37%) in the
auto-HCT group, 13 out of 57 relapses (22.8%) in the MSD
group, and 6 out of 33 relapses (18.2%) in the UD 10/
10 group.
Discussion
Recent studies have demonstrated that AML blasts from
patients with trisomy 8 AML have a specific signature
marked in part by an overexpression of genes located in
chromosome 8 [11]. Interestingly, several genes involved in
the apoptosis pathway are downregulated in trisomy 8 AML
blasts [11]. Since apoptosis is important for AML blast
killing by both chemotherapy and immune cells [16], there
is a strong rationale for comparing auto-HCT versus allo-
HCT specifically in patients with trisomy 8 AML.
Given that patients with isolated trisomy 8 AML are
classified in the European LeukemiaNet intermediate-risk
group, an allo-HCT for fit AML patients with trisomy 8 in
first CR with an appropriate donor has been recommended.
However, as mentioned above, this recommendation has not






































































Times from transplant (years)
Number of at-risk patients
3 4 5
81 42 29 23 19 15
186 106 73 64 55 47
134 76 54 37 26 19
0 1 2
Times from transplant (years)
Number of at-risk patients
3 4 5
81 42 29 23 19 15
186 106 73 64 55 47
134 76 54 37 26 19
Fig. 1 Relapse and nonrelapse
mortality. Cumulative
incidence of relapse (a) and of
nonrelapse mortality (b)
according to the type of
transplantation.
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report on the largest cohort of AML patients with isolated
trisomy 8 who underwent either an auto-HCT or an allo-
HCT in first CR. Our data clearly demonstrate better LFS
with allo-HCT than with auto-HCT, due to a significantly
lower risk of relapse. This was true irrespective of donor
type (MSD or UD 10/10). There was a similar trend for OS
that did not reach statistical significance perhaps because of
insufficient statistical power for the OS outcome. In the
other hand, more efficient salvage strategies could have
been possible among auto-HCT patients. This is illustrated
by the observation of a higher proportion of patients in the
auto-HCT group than in the two allo-HCT groups receiving
a further allo-HCT as treatment for AML relapse. Since
quality of life is better after auto-HCT than after allo-HCT
[17], further studies are needed to define the role of auto-
HCT in subgroups of trisomy 8 AML patients with a lower
risk of relapse (such as those without detectable minimal
residual disease (MRD) at HCT) and a high risk of non-
relapse mortality.
Obviously genetic randomization (i.e., HLA-identical
sibling availability versus not) [18–21] or true randomi-
zation have remained the gold standard for assessing the
role of allo-HCT in AML subtypes. However, since such
studies are not likely to be performed in isolated trisomy 8
AML, we must rely on alternative methods for assessing
the role of allo-HCT in that setting. Comparison of out-
comes between auto-HCT and allo-HCT has been shown
to produce valid observations. Furthermore, we were
reassured by the fact that the three groups were relatively
well balanced for the main AML characteristics (except
median time from diagnosis to transplantation which was
highest in the auto-HCT group, providing a possible bias
in favor of auto-HCT). In order to reduce the risk
of further bias as much as possible, we restricted the
study to patients in first CR and we excluded patients
receiving allo-HCT from alternative donors. Although we
did not have MRD data for the patients included in this
study, it is unlikely that this introduced a bias in our main
observations (lower relapse incidence and better LFS in
allo-HCT patients) since patients with detectable MRD at
HCT would have been more likely to receive an allo-HCT
than an auto-HCT. We however acknowledge that other
factors that might have prompted patients to allo-HCT or
auto-HCT are missing in the current analyses. These
factors include HCT-CI [22] (the data was missing
for 53% of the patients included in the current study) as
well as extensive molecular data. Finally, there was no
center effect identified in the Cox models for any of the
outcomes.
Although trisomy 8 blasts have a specific signature,
trisomy 8 AMLs are heterogeneous in terms of presence
of additional molecular mutations [2]. Some of these
molecular mutations might have a stronger prognostic
impact than the trisomy 8 itself and might also influence
the susceptibility of AML blasts to graft-versus-leukemia
effects. Unfortunately, we do not have the full molecular
profile for the patients in this study. However, we per-
formed sensitivity analyses in the subgroup of patients
with known NPM1 and FLT3-ITD status. Interestingly,
although the results should be taken with some caution
given the relatively low patient numbers, we observed
that allo-HCT remained associated with lower relapse
incidence as well as with better LFS than auto-HCT in
the subgroup of patients with wild-type FLT3 status.
The number of patients with mutated NPM1 or FLT3-ITD
per group was unfortunately too low to allow assessing
the impact of auto-HCT versus allo-HCT in these
subgroups.
Interestingly, the transplantation outcomes of allo-HCT
patients were not statistically impacted by the intensity of
the conditioning regimen in univariate analyses. This in in
contrast to what has been observed in the BMT-CTN 0901
trial [23]. This might indicate that graft-versus-leukemia
effects are more important than conditioning intensity in
Table 2 Multivariate analysis of transplantation outcomes.
Relapse NRM LFS OS
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Auto-HCT (reference) 1 1 1
Allo-HCT MSD 0.47 (0.31–0.72) 0.0006 2.67 (1–6.9) 0.043 0.69 (0.48–0.99) 0.044 0.73 (0.5–1.1) 0.12
Allo-HCT UD 10/10 0.40 (0.24–0.67) 0.0005 2.55 (0.86–7.5) 0.09 0.60 (0.39–0.94) 0.027 0.65 (0.4–1.1) 0.08
Time diag to HCT (mo) 0.96 (0.87–1) 0.35 0.97 (0.83–1.1) 0.74 0.96 (0.89–1) 0.30 0.98 (0.9–1.1) 0.60
Patient age (per 10 y.) 0.95 (0.84–1.1) 0.48 1.39 (1.1–1.8) 0.014 1.04 (0.93–1.2) 0.49 1.09 (0.96–1.2) 0.17
Y. of HCT 1.01 (0.97–1) 0.74 0.92 (0.86–0.99) 0.022 0.98 (0.95–1) 0.34 0.98 (0.94–1) 0.25
Center (frailty) 0.36 0.26 0.36 0.26
NRM nonrelapse mortality, LFS leukemia-free survival, OS overall survival, HCT hematopoietic stem cell transplantation, Auto-HCT autologous
HCT, Allo-HCT allogeneic HCT, MSD HLA-matched sibling donor, UD 10/10 HLA-matched unrelated donor, Y year.
Statistically significant p values are in bold
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trisomy 8 AML. However, this hypothesis should be taken
with extreme caution given the relatively small number of
patients (and thus little power to identify risk factors in
subgroups) and the lack of data on molecular abnormal-
ities, HCT-CI and on MRD status in a relatively high
proportion of patients in the current study, precluding us
to build a robust multivariate model assessing the impact
of conditioning intensity in allo-HCT patients with tris-
omy 8 AML. In addition, there was a high heterogeneity
in the conditioning regimens in both the RIC and the
myeloablative arms with some regimens classified in the
RIC group such as the fludarabine plus melphalan one
having stronger anti-leukemic activity according to recent
studies [24, 25].
In summary, we report here the largest study to date
comparing auto-HCT with allo-HCT in AML patients with
isolated trisomy 8 in first CR. We observed that allo-HCT in
first CR with either a MSD or a UD 10/10 resulted in better

















































Times from transplant (years)
Number of at-risk patients
81 42 29 23 19 15
186 106 73 64 55 47
134 76 54 37 26 19
0 1 2 3 4 5
Times from transplant (years)
Number of at-risk patients
81 58 37 32 25 21
186 122 85 74 68 57
134 85 60 43 31 21
0 1 2 3 4 5
Fig. 2 LFS and OS according to
the type of transplantation.
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